|
Volumn 28, Issue 1, 2001, Pages 95-101
|
Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus
a a a a a |
Author keywords
CD40l (CD154) antigen; Monoclonal antibody; Pharmacokinetics; Systemic lupus erythematosus
|
Indexed keywords
CD40 LIGAND MONOCLONAL ANTIBODY;
GLYCOPROTEIN GP 39;
MONOCLONAL ANTIBODY IDEC 131;
UNCLASSIFIED DRUG;
ADULT;
AREA UNDER THE CURVE;
ARTICLE;
ASTHENIA;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DIARRHEA;
DOSE RESPONSE;
DRUG HALF LIFE;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
HEADACHE;
HUMAN;
MALE;
NAUSEA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SYSTEMIC LUPUS ERYTHEMATOSUS;
THORAX PAIN;
VERTIGO;
VOMITING;
ADOLESCENT;
ADULT;
ANTIBODIES, MONOCLONAL;
CD40 LIGAND;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
FLOW CYTOMETRY;
HALF-LIFE;
HUMANS;
IMMUNOTHERAPY;
INFUSIONS, INTRAVENOUS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
LYMPHOCYTE ACTIVATION;
MALE;
MIDDLE AGED;
SAFETY;
T-LYMPHOCYTES;
|
EID: 0035163042
PISSN: 0315162X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (157)
|
References (19)
|